Geography is a genuine barrier to trial participation — studies consistently show that patients will travel up to 50 miles for a trial they're motivated about, but Phase 1 and early Phase 2 protocols often require weekly or twice-weekly visits during dosing, which makes even moderate distances prohibitive over months. The more useful framing in 2026 isn't "is there a trial near me?" but "how many visits actually require me to be physically present at the site?" That number has dropped substantially. Decentralized trial components — home nursing, local lab draws, telehealth check-ins — have reduced the fraction of visits that require the primary site, and the right trial conducted mostly remotely may be a better option than a nearby trial that demands your presence twice a week for six months.
This article is for informational purposes only and does not constitute medical advice. Clinical trial eligibility and availability vary. Always consult a qualified healthcare professional before making any medical decisions or considering participation in a clinical trial.
Quick Summary
There are over 450,000 registered clinical trials worldwide — roughly 60,000 actively recruiting at any time. Proximity matters for visit-intensive phases, but "near you" in 2026 has a different definition than it did five years ago. Decentralized designs, home nursing, and travel reimbursement mean the right trial may be hundreds of miles away — and might require fewer in-person visits than a local conventional trial.
ClinicalMetric Analysis
- Distance matters differently depending on trial phase — Phase 1 often requires near-daily visit intensity that makes geographic flexibility practically impossible, while Phase 3 maintenance periods may have monthly visits where travel from 100+ miles is feasible once monthly. Phase 1 first-in-human studies typically require 2–5 days of consecutive clinical site presence for initial dosing, followed by frequent PK sampling visits. A patient willing to relocate temporarily for 2 weeks of intensive Phase 1 monitoring may have access to trials that appear "far away" on a map. Phase 3 maintenance protocols that specify monthly visits after an initial 3-month induction period are operationally compatible with longer-distance travel for motivated patients. Before deciding a trial is "too far," ask the research coordinator for the visit schedule during each phase of the protocol — the induction burden and the maintenance burden are often very different.
- Academic medical centers run more trials per institution, but many academic protocols have added community hospital co-sites specifically because the academic center already met its enrollment target while the overall trial is still short — and community site slots may be open when the academic site waitlist is closed. Large Phase 3 trials in common conditions (diabetes, cardiovascular, oncology) routinely add 20–50 community sites after academic sites near full enrollment. A patient who is told "we're not enrolling right now" at a major academic center should specifically ask whether community hospital sites in their area are participating — or request to be referred to the nearest open site in the trial's sponsor network. The research coordinator at a fully enrolled site typically knows which other sites are still recruiting.
- Asking a trial coordinator about "decentralized visit options" is now a standard question with a real answer at most Phase 3 sites — travel for in-person visits that could be replaced by home nursing or telehealth is now avoidable, not inevitable. FDA's 2023 DCT guidance created regulatory clarity that accelerated adoption of hybrid visit models. Most Phase 3 trials designed or amended in 2024–2026 have at least some visits that can be converted to home nursing visits (for blood draws, vital signs, and investigational product administration where appropriate) or telehealth safety check-ins. Patients should specifically ask: "Which of my required visits can be done remotely or with a home nurse?" rather than assuming the paper protocol visit schedule represents the actual visit burden they'll experience.
Step 1: Search by Location on ClinicalTrials.gov — Correctly
ClinicalTrials.gov has a location search feature most patients use inefficiently. Here's the sequence that actually works:
- Go to clinicaltrials.gov and enter your condition using clinical terminology — "Type 2 Diabetes Mellitus" finds more relevant results than "diabetes" alone
- Click "More Filters" and scroll to the Location section
- Enter your ZIP code, city, or country and select a distance radius (25, 50, or 100 miles)
- Set Status to "Recruiting" — this filters out completed, terminated, and not-yet-open studies, which represent the majority of registry entries
- Sort by "Relevance" first, then check the full site list in each result — a trial with 50 sites may have one near you even if its primary institution is across the country
Each trial listing shows all recruiting locations. Check the complete site list before concluding a trial isn't accessible. Multi-site Phase 3 trials routinely activate 50–200 sites globally; the chance that none is within your range is often lower than first appearances suggest.
Step 2: Evaluate Visit Frequency Before Ruling a Trial Out
Not all trials require the same number of in-person visits. Before dismissing a trial because the nearest site is 90 miles away, check the protocol summary for mandatory on-site visit frequency during the active treatment phase — not just the total study duration.
| Trial Type | Typical Visit Frequency | Remote Options |
|---|---|---|
| Phase 1 (safety/dose-finding) | Weekly or more during dosing | Limited — intensive monitoring required |
| Phase 2/3 chronic disease | Monthly to quarterly | Often available for follow-up visits |
| Decentralized/hybrid | 1–2 in-person, rest remote | Yes — home nurse, app, wearables |
| Observational/registry | Annual or survey-based | Fully remote common |
Step 3: Ask Directly About Travel Reimbursement
Travel costs are among the most cited barriers to trial participation — and reimbursement availability is one of the most consistently under-advertised features of sponsored trials. Sponsors have financial incentive to enroll and retain participants; covering travel removes a known dropout driver. What's typically reimbursable:
- Mileage or fuel costs for driving to the trial site
- Public transport fares (train, bus, subway)
- Hotel accommodation for overnight stays; common in rare disease and CAR-T trials with concentrated academic sites
- Flights — routine in rare disease trials recruiting nationally
- Caregiver travel — most trials reimburse one accompanying person
- Childcare or eldercare costs — NIH-funded trials and some industry trials include these
Reimbursement details are rarely in the public protocol listing. Ask the trial coordinator directly: "Does this trial provide travel reimbursement, and what does the policy cover?" Ask before you commit to screening — the answer should factor into your decision.
Decentralized Clinical Trials: What "Near Me" Actually Means in 2026
Approximately 40% of trials launched in 2025–2026 incorporate at least some decentralized elements, up from under 10% before 2020. The FDA's 2023 guidance on decentralized clinical trials provides an explicit framework sponsors and IRBs are actively using. What this means in practice:
- Home nursing visits: A trained nurse comes to your home for blood draws, vital signs, and sometimes drug administration. Home nursing networks (LifeSciHub, ICON Home Health, Medable) operate across most metropolitan and many rural regions. Some Phase 2 metabolic and autoimmune trials have eliminated site visits entirely for all but the baseline visit.
- Telemedicine safety visits: Video consultations with the study investigator replace in-person safety check-ins; lab work is performed at a local LabCorp or Quest on the same day and transmitted electronically.
- Direct-to-patient drug delivery: Oral study medications shipped to your home pharmacy and dispensed locally. Self-administered injectables shipped with video training support.
- Wearables and e-diaries: Continuous heart rate, ECG, activity, and glucose monitoring via wearables replace clinic-based assessments for many endpoints in cardiovascular, metabolic, and neurological trials.
When reviewing trial listings, look for "decentralized," "hybrid design," "remote visits," or "home nursing" in the protocol description. Sponsors that have invested in DCT infrastructure will mention it because it's a recruitment advantage they want prospective participants to know about.
Finding Trials Through Patient Networks
ClinicalTrials.gov is comprehensive but difficult to navigate without clinical research familiarity. The alternatives that consistently work well:
- ResearchMatch.org: NIH-funded platform creating bidirectional matching between patients and researchers at participating university hospitals. Free, maintains your profile, and alerts you to newly opening studies.
- Disease-specific advocacy organizations: NORD, NAMI, ACS, CCFA, and condition-specific groups maintain curated trial locators updated faster than government registries and often provide peer navigator services for research access.
- Major academic medical centers' own trial registries: Mayo Clinic, Johns Hopkins, UCSF, Massachusetts General, Charité, and UCL run more trials per institution than community hospitals and maintain patient registries for proactive matching. A single evaluation visit to a major center often opens multiple study options.
- Your specialist: Oncologists, neurologists, and rheumatologists at academic practices are connected to research networks and sometimes know about trials before public registry posting. Ask directly whether any trials you'd qualify for are active in their network.
When No Local Trial Exists: Next Steps
Register your interest early. Many trials use pre-registration waitlists. When a site opens in your region, patients who registered are contacted first — particularly valuable for platform trials adding sites progressively through the enrollment period.
Ask about expanded access. If a drug in Phase 3 has no nearby site, the manufacturer may offer expanded access through your own physician before regulatory approval. Ask specifically; sponsors don't always advertise this option proactively.
Consider a one-time visit to a distant site. Some trials allow remote follow-up after an in-person baseline. Flying to a major research center once for enrollment — then completing all subsequent assessments via telehealth and home nursing — is a real and increasingly common option for patients motivated to access a specific drug or intervention.
Search Trials by Location
ClinicalMetric searches 450,000+ trials from ClinicalTrials.gov with cleaner filtering by condition, phase, location, and recruiting status.
Frequently Asked Questions
How do I find clinical trials in my city or state?
Go to ClinicalTrials.gov, enter your condition, then add your city, state, or ZIP code and set a distance radius. Also check ResearchMatch.org (NIH-supported matching service) and your nearest academic medical center research website. Many trials now offer hybrid or fully remote participation.
Do I have to travel far to join a clinical trial?
Not always. Decentralized clinical trials increasingly allow remote participation: home nursing visits, local lab draws, telehealth check-ins, and mail-order study medication. Some trials require only 1-2 in-person visits per year. Filter ClinicalTrials.gov for decentralized or remote participation options.
What questions should I ask before joining a local trial?
Key questions: How many visits are required and how long is each? Will travel and parking be reimbursed? Is there a home visit option? What happens if I move during the trial? Are there any out-of-pocket costs for standard care during the study? Who do I contact if I have a problem between visits?